(Q46637836)

23 December 2017

title

GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide (English)

1 reference

23 December 2017

2

Josephine M Egan

1 reference

23 December 2017

Joel Habener

6

object named as

Joel F Habener

1 reference

23 December 2017

author name string

Dariush Elahi

1

1 reference

23 December 2017

Richard P Shannon

3

1 reference

23 December 2017

Graydon S Meneilly

4

1 reference

23 December 2017

Ashok Khatri

5

1 reference

23 December 2017

Dana K Andersen

7

1 reference

23 December 2017

publication date

17 April 2008

1 reference

23 December 2017

published in

Obesity

1 reference

23 December 2017

volume

16

1 reference

23 December 2017

issue

7

1 reference

23 December 2017

page(s)

1501-1509

1 reference

23 December 2017

Glucagon-like peptide-1 7-36: a physiological incretin in man.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Incretins, insulin secretion and Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

On the determination of basal glucose production rate in patients with type 2 (non-insulin-dependent) diabetes mellitus using primed-continuous 3-3H-glucose infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Insulin control of glucose metabolism in man: a new kinetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Severe impairment in liver insulin signaling fails to alter hepatic insulin action in conscious mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Insulin's direct effects on the liver dominate the control of hepatic glucose production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Complexing receptor pharmacology: modulation of family B G protein-coupled receptor function by RAMPs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Influences of glucose loading and of injected insulin on hepatic glucose output

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

The gut hormone peptide YY regulates appetite.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

inferred from DOI database lookup

7 January 2021

based on heuristic

Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

inferred from DOI database lookup

7 January 2021

based on heuristic

Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2008.229

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/OBY.2008.229

1 reference

23 December 2017

1 reference

23 December 2017